The partners aim to empower pathologists with decision support tools enabled by artificial intelligence so that patients receive a fast and accurate diagnosis.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.
The group has already developed a test that detects circulating tumor cells in blood and uses centrifugal microfluidics similar to the urine-based test.
A special thermal annealing process and graphene oxide structure may enable inexpensive manufacturing and use, particularly in resource-poor areas of the world.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
